FDA Approves First Cell Therapy for Solid Tumors-The FDA has approved Iovance Biotherapeutics’ Amtagvi to treat advanced melanoma that either cannot be removed from the body or has spread throughout the body and was previously treated with other therapies. It is the first cell therapy to be ...
Overall, results of this analysis may be helpful to clinical and formulary decision-makers in demonstrating the value of STRs over MTRs among marginalized sub-populations such as those with concurrent mental health disorders. Among HIV population with/without concurrent mental health disorders, MTR-...
As a result, our updated guidance range now reflects the trends in the second half of 2024 could be higher than levels seen in the first half. It is worth knowing that if trends persist at elevated levels, we may be required to take an in year 2024 premium deficiency reserve in our Med...
Far from being theoretic explorations of moral hazard theory, the advent of precision medicine brings these considerations into the realm of imminent choices for value-based formulary design. In summary, our review finds that recent empirical studies offer scant contemporary evidence that beneficiary “...
FDA Approves First Biosimilar of Novolog By Denise MyshkoFebruary 19th 2025 FDA Accepts NDA for Gilead's New HIV Prevention Shot By Briana ContrerasFebruary 19th 2025 Opzelura Topical Cream Drives Incyte's Record Growth in 2024 with 50% Revenue Surge By Briana ContrerasFebruary 19th 2025 Cuts to...
Express Scripts unveiled the details of its first digital health formulary on Thursday. The program, first announced by Cigna’s pharmacy benefit manager in May, gives the bustling field of health apps, digital therapeutics and remote monitoring devices a better chance at adoption. ...
‘generics’ for biologics) take off in the new year. Humira, the highest-selling drug to treat multiple autoimmune disorders, is expected to have 6-7 biosimilars in the market by mid-2023. Historically, biosimilars have struggled to gain market share due to challenging formulary rebate ...
To our knowledge this is one of the first studies investigating pathways to psychological therapies at population level using data linkage of health records across primary and secondary care. Despite the overall national investment in NHS Talking Therapies [32], research on pathways between primary and...
Upon FDA authorization, structured manufacturer code sets are published by FDA, CDC, the American Medical Association (AMA), multiple formulary compendium, and the Centers for Medicare & Medicaid (CMS). System vendors incorporate the published code sets, which CDC estimates takes approximately 6 to ...
There is no generic equivalent available for the type of insulin my son has to take for his diabetes and my insurance provider considers it non-formulary. That ONE medication of his is $60 per month. This does not include his other insulin, his needles, or his test strips. There IS a ...